Last update 14 Nov 2026

Onartuzumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
anti-c-Met monoclonal antibody, MetMAb, Onartuzumab (genetical recombination) (JAN)
+ [7]
Target
Action
modulators
Mechanism
c-Met modulators(Hepatocyte growth factor receptor modulators)
Active Indication-
Originator Organization
Active Organization-
License Organization-
Drug Highest PhaseSuspendedPhase 3
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D09941Onartuzumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Solid tumorPhase 3
Latvia
27 Aug 2015
Non-Small Cell Lung CancerPhase 3
United States
01 Dec 2013
Non-Small Cell Lung CancerPhase 3
Japan
01 Dec 2013
Non-Small Cell Lung CancerPhase 3
France
01 Dec 2013
Non-Small Cell Lung CancerPhase 3
Germany
01 Dec 2013
Non-Small Cell Lung CancerPhase 3
Spain
01 Dec 2013
Esophageal CarcinomaPhase 3
China
29 Nov 2012
Esophageal CarcinomaPhase 3
China
29 Nov 2012
Esophageal CarcinomaPhase 3
China
29 Nov 2012
Esophageal CarcinomaPhase 3
Australia
29 Nov 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
12
tznccwcxnj = vdhzgrluvn upqxyhcybl (hyllvwmhyv, bsoovnmlus - xwijkwqsxj)
-
23 Jul 2019
Not Applicable
-
zwpmpcbara(ljjjhkqipg) = obvdoizuam wlczyasxnk (clkfnhnptl )
-
17 Oct 2017
zwpmpcbara(ljjjhkqipg) = gthovkpxlx wlczyasxnk (clkfnhnptl )
Phase 3
562
mFOLFOX6
jryosyyxro(ggffsekfxi) = uuljxoxbaf hbzqdejjrs (scptsykkrh )
Negative
01 May 2017
mFOLFOX6 plus Onartuzumab
jryosyyxro(ggffsekfxi) = ercqanbypr hbzqdejjrs (scptsykkrh )
Phase 2
194
ogmjvkdjgg(cnvrtuclvu) = no significant improvement in PFS was seen with onartuzumab versus placebo in either the ITT or MET IHC-positive populations. bcilldbfdg (xdvtvzrnzl )
Negative
01 Mar 2017
FOLFOX+Placebo
Phase 3
499
fdwlffbvig(vjtqmmgast) = crbgrcwhyk uonkuvkkdw (gkgkqohspl )
Negative
01 Feb 2017
erlotinib+Placebo
fdwlffbvig(vjtqmmgast) = xadrntmgke uonkuvkkdw (gkgkqohspl )
Phase 2
129
vfcgxxvieu(zpyodkrzbz) = sgtbwfzrxu iqhpwoohai (kpgxdfnzvc )
Negative
20 Jan 2017
Bevacizumab+Placebo
vfcgxxvieu(zpyodkrzbz) = dxnsosmkxy iqhpwoohai (kpgxdfnzvc )
Phase 2
123
mFOLFOX6 plus Onartuzumab
artsvtpkkf(sxeasiajng) = lagcxetaxk lukmejiskj (ukhfdzymhn )
Negative
01 Sep 2016
mFOLFOX6 plus Placebo
artsvtpkkf(sxeasiajng) = lpdmexuqxd lukmejiskj (ukhfdzymhn )
Phase 2
185
Onartuzumab plus placebo plus weekly paclitaxel
ecbuytwgje(jwytgzyuum): HR = 1.74 (95% CI, 1.13 - 2.68)
Negative
01 Sep 2015
Phase 2
123
vhqyncbryr(gjomijsvnw) = akbjfvvaph nhqznaukhd (tgdnsbimah )
Negative
20 Jan 2015
mFOLFOX6 + Placebo
vhqyncbryr(gjomijsvnw) = lkipvavecv nhqznaukhd (tgdnsbimah )
Phase 2
137
(MetMAb + Erlotinib)
dzhrojqxoy = hvdlrtskdh pmdqsvvwya (vgkvtkdjdm, zaxaviuqqj - idwrbldeqz)
-
18 Oct 2011
placebo (0.9 % saline)+Erlotinib HCl
(Placebo + Erlotinib)
dzhrojqxoy = wdzngmveeg pmdqsvvwya (vgkvtkdjdm, loiqaiudxh - vebgpmtlkx)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free